Article

Pregnancy Outcome, Antibodies, and Placental Pathology in SARS-CoV-2 Infection during Early Pregnancy

Won-Kyu Jang 1, Su-Yeon Lee 1, Sunggyun Park 2, Nam Hee Ryoo 2, Ilseon Hwang 3, Ji Min Park 3 and Jin-Gon Bae 1,*

1 Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Dongsan Medical Center, Daegu 42601, Korea; cindeln@naver.com (W.-K.J.); feedback54@naver.com (S.-Y.L.)
2 Departments of Laboratory Medicine, Keimyung University School of Medicine, Dongsan Medical Center, Daegu 42601, Korea; nosdolu@dsmc.or.kr (S.P.); nhryoo@dsmc.or.kr (N.H.R.)
3 Department of Pathology, Keimyung University School of Medicine, Dongsan Medical Center, Daegu 42601, Korea; ilseon@dsmc.or.kr (I.H.); Park starnmin28@gmail.com (J.M.P.)
* Correspondence: jgonmd@gmail.com; Tel.: +82-10-9411-3508

Abstract: There are reports that pregnant women infected with SARS-CoV-2 not only have increased morbidity but also increased complications and evidence of maternal and fetal vascular malperfusion on placental pathology. This was a retrospective study of pregnant women diagnosed with SARS-CoV-2 infection after March 2020. The results of reverse transcription polymerase chain reaction testing and IgM and IgG antibody testing of the amniotic fluid, cord blood, placenta, and maternal blood were confirmed at delivery. Placentas were evaluated histopathologically. The study included seven pregnant women diagnosed with SARS-CoV-2 infection during pregnancy at a mean gestational age of 14.5 weeks. Out of the seven women, five were infected during the first trimester. The mean gestational age at delivery was 38.4 weeks. The reverse transcription polymerase chain reaction results for maternal plasma, cord blood, placenta, and amniotic fluid were negative and IgG antibodies were detected in maternal plasma and cord blood. On placental pathology, maternal vascular malperfusion was found in only one case, fetal vascular malperfusion in four cases, and inflammatory changes were found in two cases. Pregnancy outcomes for women diagnosed with SARS-CoV-2 infection during early pregnancy are positive and it is likely that maternal antibodies are passed to the fetus, which results in a period of immunity.

Keywords: COVID-19; SARS-CoV-2; vertical infection transmission; COVID-19 antibody; neutralizing antibody; first trimester pregnancy; placenta; pathology

1. Introduction

In December 2019, Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2), a novel coronavirus that has both toxic and infectious properties, first appeared in Wuhan, China. On 1 April 2021, there were more than 100 million infections worldwide and more than 2 million deaths [1,2]. This count is increasing daily and the approximate worldwide mortality rate is estimated at 2–3% as reported by the World Health Organization [2].

The coronavirus disease 2019 (COVID-19) occurs with infection by SARS-CoV-2. The infection may be asymptomatic, result in a mild viral syndrome, or cause severe symptoms such as respiratory failure, shock, multi-organ dysfunction, and death [3].

Previous studies of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV indicate that infections during pregnancy are severe and tend to be associated with poor neonatal outcomes including an increased risk of miscarriage, fetal growth restriction, and preterm birth [4–7]. However, most of the published studies documenting these results involved infection during the second or third trimester of pregnancy and there
were only a few cases reported of first trimester infection where the pregnancy continued to a term birth [8].

Based on these findings, we reviewed seven cases that occurred at our hospital. We were able to determine the results of cord blood antibody and placental pathology, which to our knowledge have not been previously reported, as well as the pregnancy outcomes of cases with first trimester infection that continued to delivery.

2. Materials and Methods

Following approval from the institutional review board, we conducted a retrospective chart review of pregnant women infected with COVID-19 during pregnancy who delivered at Keimyung University Dongsan Medical Center, Daegu, Korea after March 2020.

The diagnosis of COVID-19 was confirmed by real-time reverse transcriptase polymerase chain reaction (real-time RT-PCR) using Allplex 2019-nCoV (Seegene, Seoul, Korea) as per the manufacturer’s instructions with a nasopharyngeal swab. All RNA was extracted from the swab using the Real Prep Automated Nucleic Acid Extraction System (Bioswoom, Seoul, Korea). CFX96 (Bio-Rad Laboratories, Hercules, CA, USA) was used as a thermocycler for the real-time RT-PCR. Cycle threshold (Ct) values from FAM (E gene), Cal Red 610 (RDRP gene), Quasar 670 (N gene), and HEX (internal control) were acquired. We used 40 as the cut-off value for Ct in all target genes. Mothers confirmed with COVID-19 infection were isolated and observed for symptoms and blood tests and chest radiographs were performed. Two negative real-time RT-PCR tests were considered to be evidence of recovery from COVID-19 and maternal quarantine was lifted at that point. Following delivery, newborns were immediately moved to a negative pressure ward if necessary, quarantined, and real-time RT-PCR was performed with a nasopharyngeal swab. At the time of delivery, cord blood, maternal blood, amniotic fluid, and placental specimens were collected for evidence of infection.

We reviewed the mother’s medical records, clinical characteristics, blood test results, placental biopsies, and neonatal outcomes. The RNA was extracted from these samples (amniotic fluid, placenta, cord blood, maternal blood, and nasopharyngeal swab) using the same method outlined above. Serum IgM and IgG antibodies against SARS-CoV-2 were measured using the immunochromatographic test kit STANDARD Q COVID-19 IgM/IgG Plus Test (SD biosensor, Suwon, Korea) according to the manufacturer’s instructions. The Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics, Rotkreuz, Switzerland) was performed according to the manufacturer’s instructions on Cobas e801 (Roche Diagnostics, Rotkreuz, Switzerland) for detecting total antibody against SARS-CoV-2. Quantitative results were obtained and a cut-off index (COI) of 1 was used for qualitative results. Placental specimens were evaluated and reviewed histopathologically by pathologists.

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS 25.0, IBM Corporation, Armonk, NY, USA). Variables were expressed as the mean and number and descriptive statistics were used as well.

3. Results

The study included seven pregnant women diagnosed with COVID-19 during pregnancy with a mean gestational age of 14.5 weeks. Out of these, five (71.4%) were infected during the first trimester. All seven patients had no underlying diseases and no preterm birth history (Table 1). Symptoms such as myalgia, cough, sore throat, sputum production, and rhinorrhea were all mild except for case number 3, who had fever and dyspnea (Table 2).
Table 1. Clinical characteristics.

| Case Number | 1   | 2   | 3   | 4   | 5   | 6   | 7   |
|-------------|-----|-----|-----|-----|-----|-----|-----|
| Maternal age (years) | 40  | 33  | 35  | 36  | 22  | 39  | 37  |
| BMI          | 30.4| 23.8| 20.9| 24.9| 29.0| 24.2| 19.9|
| Gravida      | 3   | 2   | 3   | 3   | 1   | 2   | 3   |
| Para         | 1   | 1   | 1   | 2   | 0   | 1   | 2   |
| History of preterm birth | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| Previous illness | No  | No  | No  | No  | No  | No  | No  |
| GA at infection | 30.4| 24.5| 13.6| 11  | 8.2 | 7.3 | 6.5 |
| Time to negative results (days) | 47  | 19  | 19  | 13  | 52  | 10  | 28  |

BMI, body mass index; GA, gestational age.

Table 2. Signs and symptoms of disease.

| Case Number | 1   | 2   | 3   | 4   | 5   | 6   | 7   |
|-------------|-----|-----|-----|-----|-----|-----|-----|
| Fever       | No  | No  | Yes | No  | No  | No  | No  |
| Myalgia     | Yes | No  | Yes | No  | Yes | No  | Yes |
| Cough       | Yes | No  | Yes | Yes | No  | Yes | No  |
| Dyspnea     | No  | No  | Yes | No  | No  | No  | No  |
| Sore throat | Yes | No  | Yes | No  | No  | No  | Yes |
| Sputum production | Yes | Yes | Yes | No  | No  | Yes | No  |
| Rhinorrhea  | No  | Yes | No  | No  | No  | No  | No  |

The mean gestational age at delivery was 38.4 weeks, along with a mean time of 166.4 days from infection onset to delivery. The mean birth weight was 3.1 kg. A total of 60% of the deliveries were delivered by C-section. Only one infant was born late preterm at 36 weeks and 4 days. There was only one NICU admission and that was the infant born late preterm. He was admitted to the NICU for transient tachypnea, which resolved quickly, and he was discharged home with the mother (Table 3).

Table 3. Neonatal outcomes.

| Case Number | 1   | 2   | 3   | 4   | 5   | 6   | 7   |
|-------------|-----|-----|-----|-----|-----|-----|-----|
| GA at delivery (weeks) | 38.5| 38  | 36.4| 39  | 38.1| 40  | 39.3|
| Onset of infection to delivery (days) | 57  | 93  | 159 | 196 | 203 | 228 | 229 |
| Delivery mode | CS  | CS  | CS  | VD  | CS  | VD  | VD  |
| Birth weight (kg) | 3.67| 2.90| 2.40| 3.55| 3.32| 3.15| 2.51|
| Apgar score 1/5 min | 8/9 | 7/8 | 8/9 | 8/9 | 8/9 | 8/9 |
| Sex          | F   | F   | F   | M   | F   | M   | F   |
| NICU admission | No  | No  | Yes  | No  | No  | No  | No  |
| Anomalies    | No  | No  | No   | No  | No  | No  | No  |

GA, gestational age; CS, cesarean section; VD, vaginal delivery; F, female; M, male. * Hospitalized for symptoms of transient tachypnea.

Real-time RT-PCR results from maternal plasma, cord blood, placenta, and amniotic fluid were all negative. Amniotic fluid could not be collected due to vaginal delivery in one case. IgM antibody was found in two cases and IgG antibody was found in four other cases in maternal plasma collected at the time of delivery. The IgM antibody was not detected in cord blood and IgG antibodies were found in all but one sample of cord blood. Antibody titers were all positive in both maternal plasma and cord blood (Table 4).

Pathologic features of maternal vascular malperfusion included excessive villous infarction (thrombosis of stem villi, endothelial injury, thickened walls of stem villous arteries, and luminal obliteration), increased fibrin deposition, accelerated villous maturation (increased syncytial knots defined as knots in >20% of villi preterm or 30% of villi at term), increased calcification, and intervillous thrombosis. Pathologic features of fetal vascular malperfusion included extensive avascular villi (groups of homogeneously pink villi may
contain stromal cells but lack capillaries), karyorrhexis (fragmented red blood cells and cellular debris over fetal vessels), chorangiosis (more than 10 fields of placental parenchyma with more than 10 terminal villi, each containing more than 10 capillaries in at least three different areas), distal villous hypoplasia (paucity of distal villi in relation to surrounding stem villi seen in lower 2/3 of parenchymal thickness, involving at least 30% of full thickness), and delayed villous maturation. Pathologic features of inflammatory changes included chronic villitis (infiltrate of lymphocytes with histiocytes), diffuse villous edema (enlarged villi, loose mesenchymal-appearing stroma, and central thin-walled vessels), and chorioamnionitis/subchorionitis. Chorioamnionitis/subchorionitis was classified into stage 1 (acute inflammation limited to subchorionic space or membranous trophoblast, not extending into fibrous chorion), stage 2 (acute inflammation of fibrous chorion/amnion), and stage 3 (necrotizing acute inflammation with neutrophil karyorrhexis and amniocyte necrosis); and grade 1 (scattered neutrophils) and grade 2 (confluent neutrophils with more than 200 cells in extent). In one case (case 7), the placenta showed increased fibrin deposition and increased calcification, which are features of maternal malperfusion. Chorangiosis and distal villous hypoplasia, features of fetal malperfusion, were present in cases 4 and 5 and cases 2 and 6, respectively. Features of chronic inflammatory changes were observed in two cases as chorioamnionitis/subchorionitis stage 1 and grade 1 (cases 1 and 7, respectively) (Table 5 and Figure 1).

Table 4. Laboratory findings at delivery.

| Case Number | 1     | 2     | 3     | 4     | 5     | 6     | 7     |
|-------------|-------|-------|-------|-------|-------|-------|-------|
| Mother’s Plasma PCR | Neg   | Neg   | Neg   | Neg   | Neg   | Neg   | Neg   |
| Cord blood PCR | Neg   | Neg   | Neg   | Neg   | Neg   | Neg   | Neg   |
| Amniotic fluid PCR | X*   | Neg   | Neg   | Neg   | Neg   | Neg   | Neg   |
| IgM antibody in maternal plasma | Yes   | No    | No    | No    | No    | No    | Yes   |
| IgG antibody in maternal plasma | Yes   | Yes   | Yes   | Yes   | Yes   | Yes   | Yes   |
| IgM antibody in cord blood | No    | No    | No    | No    | No    | No    | No    |
| IgG antibody in cord blood | Yes   | Yes   | Yes   | No    | Yes   | Yes   | Yes   |
| COI of total anti-SARS-CoV-2 antibody in Maternal plasma | 77.6  | 5.4   | 6.79  | 6.29  | 13.4  | 1.1   | 3.17  |
| COI of total anti-SARS-CoV-2 antibody in Cord blood | 71.5  | 5.42  | 8.15  | 12.3  | 17.5  | 1.63  | 5.84  |

COI, cut-off index. * Failure to collect amniotic fluid.

Table 5. Placental pathologic findings.

| Case number | 1     | 2     | 3     | 4     | 5     | 6     | 7     |
|-------------|-------|-------|-------|-------|-------|-------|-------|
| Maternal vascular malperfusion |       |       |       |       |       |       |       |
| Excessive villous infarction | No    | No    | No    | No    | No    | No    | No    |
| Increased fibrin deposition | No    | No    | No    | No    | No    | No    | Yes   |
| Accelerated villous maturation | No    | No    | No    | No    | No    | No    | No    |
| Increased calcification | No    | No    | No    | No    | No    | No    | Yes   |
| Intervillous thrombosis | No    | No    | No    | No    | No    | No    | No    |
| Fetal vascular malperfusion |       |       |       |       |       |       |       |
| Extensive avascular villi | No    | No    | No    | No    | No    | No    | No    |
| Karyorrhexis | No    | No    | No    | No    | No    | No    | No    |
| Chorangiosis | No    | No    | No    | Yes   | Yes   | Yes   | No    |
| Distal villous hypoplasia | No    | Yes   | No    | No    | Yes   | No    | No    |
| Delayed villous maturation | No    | No    | No    | No    | No    | No    | No    |
| Inflammatory change |       |       |       |       |       |       |       |
| Chronic villitis | No    | No    | No    | No    | No    | No    | No    |
| Diffuse villous edema | No    | No    | No    | No    | No    | No    | No    |
| Chorioamnionitis/subchorionitis | Yes   | No    | No    | No    | No    | No    | Yes   |
Table 5. Placental pathologic findings.

| Case number | Maternal vascular malperfusion | Increased fibrin deposition | Accelerated villous maturation | Increased calcification | Intervillous thrombosis | Fetal vascular malperfusion | Karyorrhexis | Chorangiosis | Distal villous hypoplasia | Delayed villous maturation | Inflammatory change |
|-------------|--------------------------------|-----------------------------|-------------------------------|-------------------------|------------------------|----------------------------|-------------|--------------|--------------------------|--------------------------|------------------------|
| 1           | No                             | No                          | No                            | No                      | No                     | No                         | No          | No           | No                       | No                       | No                     |
| 2           | No                             | No                          | No                            | No                      | No                     | No                         | No          | No           | Yes                      | No                       | No                     |
| 3           | No                             | No                          | No                            | No                      | No                     | No                         | No          | No           | No                       | No                       | No                     |
| 4           | No                             | No                          | No                            | No                      | No                     | No                         | No          | Yes          | No                       | No                       | No                     |
| 5           | No                             | No                          | No                            | No                      | No                     | No                         | No          | No           | No                       | No                       | No                     |
| 6           | No                             | No                          | No                            | No                      | No                     | No                         | No          | No           | No                       | No                       | No                     |
| 7           | No                             | No                          | No                            | No                      | Yes                    | Yes                        | No          | No           | No                       | No                       | No                     |

4. Discussion

The results of this study show that the pregnancy outcomes of women diagnosed with COVID-19 during early pregnancy are positive. In particular, in the case of mothers infected during the first trimester, there were no fetal or neonatal deaths and the newborns did not have any infectious symptoms. There appeared to be no vertical transmission of the virus. Maternal IgG antibody generated after infection appeared to be transmitted to the fetus.

Currently, there is limited information on the effects of COVID-19 infection during pregnancy on maternal, fetal, placental, and neonatal outcomes. In recent review articles, the majority of COVID-19 infections during pregnancy occurred during the third trimester, most of the rest occurred during the second trimester, and very few infections occurred during the first trimester [9,10]. In this study, five cases of first trimester infections were reported, which is currently the most in the published literature. This study found that most of the infections possess mild clinical manifestations with positive pregnancy outcomes and no fetal or neonatal deaths. This study found very positive pregnancy outcomes compared with the results of previous reports of influenza virus, SARS-CoV, MERS-CoV, and reports on abortion and severe adverse pregnancy outcomes of COVID-19. This is
likely due to the fact that most of the patient’s symptoms were mild. In fact, the one case with fever and chest discomfort delivered prematurely following preterm premature rupture of fetal membranes.

In this study, IgG antibody was negative in maternal plasma and cord blood in only one case. However, since the antibody titer was positive, it was considered to be a false negative resulting in IgG antibody being detected in all cases. As noted in previous studies, when IgG antibodies are observed, neutralizing antibodies are simultaneously found to be present and maternal antibodies to specific pathogens can be delivered through the placenta to the fetus to protect the newborn from infection [11]. A prior report noted that the correlation between IgG antibody and neutralizing antibody is similar in SARS-CoV-2 [12]. This suggests that the newborn has both IgG and neutralizing antibody delivered from the mother and the newborn is likely to possess some immunity to COVID-19 immediately following delivery.

Shanes et al. reported that the placentas of mothers infected with COVID-19 had at least one feature of maternal vascular malperfusion compared to a control group [13]. Similarly, in a study published by Menter et al., maternal vascular malperfusion was observed in all five cases [14]. However, in this study, maternal vascular malperfusion was found in only one of seven cases. The main cause of maternal vascular malperfusion in placental pathology is probably due to the increased vortex or underperfusion in maternal placental circulation as a result of shock and hypoxia. This maternal vascular malperfusion is well described in maternal placentas diagnosed with preeclampsia or fetal growth restriction during pregnancy [15]. In fact, case 7 in our study was delivered at 39 weeks and 3 days of gestation, but the neonate birth weight was 2.51 kg, which was less than 10th percentile based on the week of birth, indicating fetal growth restriction; this is thought to have resulted from maternal vascular malperfusion. The mechanism of maternal vascular malperfusion in patients infected with SARS-CoV-2 still requires further study, but intervillous thrombi increases with COVID-19, which leads to an increase in the vortex or underperfusion in maternal placental circulation, thereby causing maternal vascular malperfusion [13,14]. However, in previous studies, this maternal vascular malperfusion was not observed, even in cases of SARS infection during the first trimester [16]. Presumably, in the first trimester, SARS infection had an all-or-nothing effect and maternal vascular malperfusion was not observed if pregnancy complications do not develop after this period. The cases in this paper demonstrate the longest intervals in gestational age with an ongoing SARS-CoV-2 infection, that is, from the time of infection to delivery. Because of SARS-CoV-2 infection in the early trimester, especially in the first trimester, this case of maternal vascular malperfusion was not seen or thought to have recovered at the time of delivery. Five out of seven cases of infection in this study occurred during the first trimester. The symptoms at the time of SARS-CoV-2 infection were mild, no specific pregnancy complications developed, and maternal vascular malperfusion was not observed. The fetal vascular malperfusion findings in this study were not significantly different from those of the previous two studies [13,14]. In this study, placental inflammation was observed in two cases. In both cases, chorioamnionitis/subchorionitis stage 1 and grade 1 were observed but clinically no findings were found that indicated inflammation except for SARS-CoV-2 infection during pregnancy. These findings indicate the possibility of sequelae from SARS-CoV-2 infection during early pregnancy.

The main limitations of this study are its retrospective nature and small sample size. Since it is a retrospective study, there is no direct data on the infants immediately following birth which limits the study of antibodies in these infants. The advantages of this study include data collection from COVID-19 infected mothers beginning from the first trimester, confirmation of antibody transmission to the fetus, and placental biopsy in COVID-19 infected mothers, which has not been previously well reported.
5. Conclusions

In conclusion, the pregnancy outcome in women diagnosed with COVID-19 infection during the first trimester appears to be positive and maternal antibodies are passed through the placenta to the fetus; thus, the newborn is likely to be born with some immunity. Evidence of fetal vascular malperfusion is increased on placental pathology.

Author Contributions: Conceptualization, W.-K.J., S.-Y.L., S.P., N.H.R., I.H., J.M.P., and J.-G.B.; methodology, W.-K.J., S.P., N.H.R., I.H., and J.-G.B.; writing—original draft preparation, J.W.; writing—review and editing, W.-K.J., S.P., N.H.R., I.H., and J.-G.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Keimyung University Dongsan Hospital (protocol code 2020-10-059 and date of approval 23 October 2020).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. Corona Virus Situation Reports. 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4 (accessed on 1 April 2021).
2. WHO. Weekly Epidemiological Update. 2020. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update---22-december-2020 (accessed on 1 April 2021).
3. Bhatraju, P.K.; Ghassemieh, B.J.; Nichols, M.; Kim, R.; Jerome, K.R.; Nalla, A.K.; Greninger, A.L.; Pipavath, S.; Wurfel, M.M.; Evans, L.; et al. Covid-19 in critically ill patients in the seattle region—Case series. N. Engl. J. Med. 2020, 382, 2012–2022. [CrossRef]
4. Schwartz, D.A.; Graham, A.L. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: Lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020, 12, 194. [CrossRef] [PubMed]
5. Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet 2020, 395, 809–815. [CrossRef]
6. Qiao, J. What are the risks of COVID-19 infection in pregnant women? Lancet 2020, 395, 760–762. [CrossRef]
7. Di Mascio, D.; Khalil, A.; Saccone, G.; Rizzo, G.; Buca, D.; Liberati, M.; Vecchiet, J.; Nappi, L.; Scambia, G.; Berghella, V. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1-19) during pregnancy: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2020, 2, 100107. [CrossRef]
8. COVID Date Tracker. Available online: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/birth-data-on-covid-19.html (accessed on 1 April 2021).
9. Pettinrosso, E.; Giles, M.; Cole, S.; Rees, M. COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission. Aust. N. Z. J. Obstet. Gynaecol. 2020, 60, 640–659. [CrossRef] [PubMed]
10. Yee, J.; Kim, W.; Han, J.M.; Yoon, H.Y.; Lee, N.; Lee, K.E.; Gwak, H.S. Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: A systematic review and meta-analysis. Sci. Rep. 2020, 10, 18126. [CrossRef] [PubMed]
11. Allbrecht, M.; Arch, P.C. Vertically transferred immunity in neonates: Mothers, mechanisms and mediators. Front. Immunol. 2020, 11, 555. [CrossRef]
12. Theel, E.S.; Slev, P.; Wheeler, S.; Couturier, M.R.; Wong, S.J.; Kadkhoda, K. The role of antibody testing for SARS-CoV-2: Is there one? J. Clin. Microbiol. 2020, 58. [CrossRef] [PubMed]
13. Shanes, E.D.; Mithal, L.B.; Otero, S.; Azad, H.A.; Miller, E.S.; Goldstein, J.A. Placental pathology in COVID-19. Am. J. Clin. Pathol. 2020, 154, 23–32. [CrossRef] [PubMed]
14. Menter, T.; Mertz, K.D.; Jiang, S.; Chen, H.; Monod, C.; Tzankov, A.; Walvdovgel, S.; Schulzke, S.M.; Hösli, I.; Bruder, E. Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion. Pathobiology 2021, 88, 69–77. [CrossRef]
15. Ernst, L.M. Maternal vascular malperfusion of the placental bed. Apmis 2018, 126, 551–560. [CrossRef] [PubMed]
16. Ng, W.; Wong, S.; Lam, A.; Mak, Y.; Yao, H.; Lee, K.; Chow, K.; Yu, W.; Ho, L. The placentas of patients with severe acute respiratory syndrome: A pathophysiological evaluation. Pathology 2006, 38, 210–218. [CrossRef]